Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment

被引：0
|
作者：
Werner, Rudolf [2 ,6 ]
Higuchi, Takahiro [4 ]
Muegge, Dirk [4 ]
Javadi, Mehrbod [3 ]
Fassnacht, Martin [5 ]
Buck, Andreas [4 ]
Lapa, Constantin [4 ]
Kreissl, Michael [1 ]
机构：
[1] Hosp Augsburg, Dept Nucl Med, Augsburg, Germany
[2] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, 600 N Wolfe St, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA
[4] Univ Hosp Wuerzburg, Dept Nucl Med, Wurzburg, Germany
[5] Univ Hosp WArzburg, Div Endocrinol & Diabet, Dept Internal Med 1, Wurzburg, Germany
[6] Univ Hosp WArzburg, Else KrAner Forschungskolleg, Dept Nucl Med, Wurzburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
    Werner, Rudolf A.
    Schmid, Jan-Stefan
    Higuchi, Takahiro
    Javadi, Mehrbod S.
    Rowe, Steven P.
    Maerkl, Bruno
    Aulmann, Christoph
    Fassnacht, Martin
    Kroiss, Matthias
    Reiners, Christoph
    Buck, Andreas K.
    Kreissl, Michael C.
    Lapa, Constantin
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 756 - 761
  • [2] FDG-PET can predict response to vandetanib treatment in patients suffering from advanced medullary thyroid carcinoma
    不详
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S395 - S396
  • [3] Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
    Werner, R. A.
    Schmid, J. S.
    Muegge, D. O.
    Lueckerath, K.
    Higuchi, T.
    Haenscheid, H.
    Grelle, I.
    Reiners, C.
    Herrmann, K.
    Buck, A. K.
    Lapa, C.
    MEDICINE, 2015, 94 (45) : e2016
  • [4] Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
    Deshpande, Hari
    Marler, Vicky
    Sosa, Julie Ann
    ONCOTARGETS AND THERAPY, 2011, 4 : 209 - 215
  • [5] Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Wells, Samuel A., Jr.
    Gosnell, Jessica E.
    Gagel, Robert F.
    Moley, Jeffrey
    Pfister, David
    Sosa, Julie A.
    Skinner, Michael
    Krebs, Annetta
    Vasselli, James
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 767 - 772
  • [6] Vandetanib and the management of advanced medullary thyroid cancer
    Campbell, Michael J.
    Seib, Carolyn D.
    Gosnell, Jessica
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (01) : 39 - 43
  • [7] Vandetanib for the Treatment of Medullary Thyroid Cancer
    Chau, Nicole G.
    Haddad, Robert I.
    CLINICAL CANCER RESEARCH, 2013, 19 (03) : 524 - 529
  • [8] Impact of FDG-PET in patients with biochemical evidence of recurrent or residual medullary thyroid cancer
    J. T. Plukker
    J. W. De Groot
    T. P. Links
    P. L. Jager
    Annals of Surgical Oncology, 2004, 11 : S105 - S105
  • [9] Impact of FDG-PET in patients with biochemical evidence of recurrent or residual medullary thyroid cancer
    Plukker, JT
    De Groot, JW
    Links, TP
    Jager, PL
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : S105 - S105
  • [10] Volumetric Assessment Based On Baseline FDG PET Can Predict Survival In Medullary Thyroid Cancer Patients Scheduled For Vandetanib Treatment
    Werner, R.
    Bundschuh, R.
    Higuchi, T.
    Javadi, M.
    Rowe, S.
    Zsoter, N.
    Buck, A.
    Lapa, C.
    Kreissl, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S49 - S50
12345